MicroVue™ FGF-23 ELISA (Intact)

The MicroVue Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.


Product Specifications

Citations 12
Specimen

Plasma or Cell Culture Supernatent, 100 µL

LLOQ 0.0015 ng/mL
ULOQ N/A
Assay Time 3.5 hours
Cross Reactivity

None

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog Number 60-6600
Catalog Number (CE)  
Size 96 wells/test
Price (USD) $835.00
Price (EURO) 740,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Plasma or Cell Culture Supernatent, 100 µL
Limit of Detection (LOD) 0.0015 ng/mL
Lower Limit of Quantitation (LLOQ) 0.0015 ng/mL
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 2.0 - 4.1%
Inter Assay 3.5 - 9.1%
Standards 6
Controls 2
Sample Values

N/A

Assay Time 3.5 hours
Cross Reactivity

None

Storage

Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components

Background

Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Citations

Title Year Applications Sample Species Sample Sample Details

Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.

2010

ELISA

Human

Plasma

Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.

2010

ELISA

Human

Serum

Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.

2020

ELISA

Human

Plasma

Chronic Kidney Disease

Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis

2009

ELISA

Human

Plasma

The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease

2010

ELISA

Human

Plasma

Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients

2012

ELISA

Human

Serum

Chronic Kidney Disease

Biological variability of plasma intact and C-terminal FGF23 measurements

2012

ELISA

Human

Plasma

The use of fibroblast growth factor 23 testing in patients with kidney disease.

2014

ELISA

Human

Plasma

Correlates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals

2016

ELISA

Human

Plasma

HIV

C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population

2016

ELISA

Human

Plasma

Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia

2016

ELISA

Human

Plasma

Under-recognized Hypoparathyroidism in Thalassemia

2018

ELISA

Human

Plasma

Hypoparathyroidism